Grufity logo
Grufity logo
ANNX

ANNX - Annexon, Inc. Stock Price, Fair Value and News

$3.80+0.10 (+2.70%)
Delayed as of 27 Oct 2026, 12:04 pm ET

Price Targets

ANNX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANNX Price Action

Last 7 days

-8.0%

Last 30 days

1.4%

Last 90 days

-25.7%

Trailing 12 Months

15.0%

ANNX RSI Chart

ANNX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ANNX Valuation

Market Cap

850.2M

Price/Earnings (Trailing)

-4.2

EV/EBITDA

-8.43

Price/Free Cashflow

-4.4

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ANNX Fundamentals

ANNX Earnings

Earnings (TTM)

-202.7M

Earnings Growth (Yr)

-12.6%

Earnings Growth (Qtr)

-25.39%

ANNX Profitability

Return on Equity

-108.93%

Return on Assets

-82.37%

Free Cashflow Yield

-22.73%

ANNX Investor Care

Dividend Yield

0%

Dividend/Share (TTM)

0

Shares Dilution (1Y)

33.33%

Diluted EPS (TTM)

-1.14

ANNX Alerts

  • 1 major insider buys recently.
Revenue & Growth

How Annexon, Inc. generates revenue and covers its expenses, based on the latest reported earnings.

About Annexon, Inc.

ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.
 CEO
 WEBSITEannexonbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES77

Annexon, Inc. Frequently Asked Questions

ANNX is the stock ticker symbol of Annexon, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Oct 26 2026, market cap of Annexon, Inc. is 850.24 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.